Eupraxia Pharmaceuticals (EPRX) Competitors $3.10 -0.17 (-5.20%) Closing price 04/3/2025 03:48 PM EasternExtended Trading$3.14 +0.04 (+1.29%) As of 04/3/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EPRX vs. SAGE, MAZE, CRMD, MNMD, VERV, RLAY, PGEN, SANA, CGEM, and ORICShould you be buying Eupraxia Pharmaceuticals stock or one of its competitors? The main competitors of Eupraxia Pharmaceuticals include Sage Therapeutics (SAGE), Maze Therapeutics (MAZE), CorMedix (CRMD), Mind Medicine (MindMed) (MNMD), Verve Therapeutics (VERV), Relay Therapeutics (RLAY), Precigen (PGEN), Sana Biotechnology (SANA), Cullinan Therapeutics (CGEM), and ORIC Pharmaceuticals (ORIC). These companies are all part of the "pharmaceutical products" industry. Eupraxia Pharmaceuticals vs. Sage Therapeutics Maze Therapeutics CorMedix Mind Medicine (MindMed) Verve Therapeutics Relay Therapeutics Precigen Sana Biotechnology Cullinan Therapeutics ORIC Pharmaceuticals Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Sage Therapeutics (NASDAQ:SAGE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability. Does the MarketBeat Community favor EPRX or SAGE? Sage Therapeutics received 629 more outperform votes than Eupraxia Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Eupraxia Pharmaceuticals an outperform vote while only 65.12% of users gave Sage Therapeutics an outperform vote. CompanyUnderperformOutperformEupraxia PharmaceuticalsOutperform Votes4100.00% Underperform VotesNo VotesSage TherapeuticsOutperform Votes63365.12% Underperform Votes33934.88% Do analysts recommend EPRX or SAGE? Eupraxia Pharmaceuticals presently has a consensus price target of $10.50, indicating a potential upside of 238.71%. Sage Therapeutics has a consensus price target of $8.81, indicating a potential upside of 19.57%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Eupraxia Pharmaceuticals is more favorable than Sage Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eupraxia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50Sage Therapeutics 2 Sell rating(s) 15 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media prefer EPRX or SAGE? In the previous week, Sage Therapeutics had 3 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 4 mentions for Sage Therapeutics and 1 mentions for Eupraxia Pharmaceuticals. Sage Therapeutics' average media sentiment score of 0.40 beat Eupraxia Pharmaceuticals' score of 0.00 indicating that Sage Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eupraxia Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sage Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is EPRX or SAGE more profitable? Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Sage Therapeutics' net margin of -971.50%. Sage Therapeutics' return on equity of -68.18% beat Eupraxia Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Eupraxia PharmaceuticalsN/A -219.64% -96.00% Sage Therapeutics -971.50%-68.18%-60.84% Do insiders & institutionals have more ownership in EPRX or SAGE? 99.2% of Sage Therapeutics shares are held by institutional investors. 5.5% of Sage Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has preferable earnings & valuation, EPRX or SAGE? Eupraxia Pharmaceuticals has higher earnings, but lower revenue than Sage Therapeutics. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEupraxia PharmaceuticalsN/AN/A-$28.22M-$0.76-4.08Sage Therapeutics$41.24M10.99-$400.67M-$6.59-1.12 SummarySage Therapeutics beats Eupraxia Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Remove Ads Get Eupraxia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EPRX vs. The Competition Export to ExcelMetricEupraxia PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$110.50M$6.73B$5.54B$7.49BDividend YieldN/A2.79%5.35%4.04%P/E Ratio-4.316.9923.2518.07Price / SalesN/A198.60361.2686.83Price / CashN/A65.6738.1634.64Price / Book103.335.926.493.99Net Income-$28.22M$142.37M$3.21B$247.18M7 Day Performance-8.28%-9.32%-6.42%-6.42%1 Month Performance-21.32%-10.26%-0.68%-7.44%1 Year PerformanceN/A-15.08%6.05%-4.31% Eupraxia Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EPRXEupraxia Pharmaceuticals1.8912 of 5 stars$3.10-5.2%$10.50+238.7%N/A$116.56MN/A-4.3129Upcoming EarningsGap DownSAGESage Therapeutics3.5924 of 5 stars$8.47+3.2%$8.81+4.1%-57.0%$520.44M$41.24M-1.28690MAZEMaze TherapeuticsN/A$11.85-0.1%$25.67+116.6%N/A$518.76M$167.50M0.00121Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageCRMDCorMedix2.519 of 5 stars$8.38-22.2%$16.00+90.8%+47.7%$513.93M$12.26M-10.4630Analyst UpgradeGap DownHigh Trading VolumeMNMDMind Medicine (MindMed)2.3946 of 5 stars$6.74-2.6%$25.11+272.6%-52.8%$507.98MN/A-2.9840VERVVerve Therapeutics1.9895 of 5 stars$5.72-1.1%$25.50+346.2%-55.8%$507.47M$32.33M-2.32110Gap DownRLAYRelay Therapeutics2.1412 of 5 stars$2.95-5.0%$19.80+572.3%-67.9%$499.24M$10.01M-1.13330Gap DownPGENPrecigen3.0602 of 5 stars$1.69-7.4%$7.00+315.4%-4.3%$495.46M$3.93M-3.06190Gap DownSANASana Biotechnology3.2166 of 5 stars$2.17-10.5%$10.80+398.8%-85.0%$487.18MN/A-1.55380Gap DownCGEMCullinan Therapeutics2.0605 of 5 stars$8.27-3.2%$32.86+297.5%-56.5%$484.31MN/A-2.9130News CoveragePositive NewsORICORIC Pharmaceuticals4.0141 of 5 stars$6.75-8.5%$18.86+179.6%-53.8%$479.01MN/A-3.7180Gap Down Remove Ads Related Companies and Tools Related Companies Sage Therapeutics Competitors Maze Therapeutics Competitors CorMedix Competitors Mind Medicine (MindMed) Competitors Verve Therapeutics Competitors Relay Therapeutics Competitors Precigen Competitors Sana Biotechnology Competitors Cullinan Therapeutics Competitors ORIC Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EPRX) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eupraxia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EPRX Stock Free EPRX Stock Alerts